MDxHealth SA (NASDAQ:MDXH) Shares Purchased by Perkins Capital Management Inc.

Perkins Capital Management Inc. increased its stake in MDxHealth SA (NASDAQ:MDXH) by 70.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 747,375 shares of the company’s stock after purchasing an additional 309,500 shares during the period. MDxHealth accounts for about 1.5% of Perkins Capital Management Inc.’s portfolio, making the stock its 18th largest position. Perkins Capital Management Inc. owned about 47.91% of MDxHealth worth $1,555,000 as of its most recent filing with the Securities & Exchange Commission.

Analysts Set New Price Targets

Separately, Lake Street Capital started coverage on shares of MDxHealth in a report on Thursday, October 31st. They issued a “buy” rating and a $7.00 price target for the company.

MDxHealth Price Performance

Shares of MDXH stock opened at $2.08 on Thursday. MDxHealth SA has a fifty-two week low of $1.95 and a fifty-two week high of $4.64. The stock’s 50-day simple moving average is $2.31 and its 200-day simple moving average is $2.59.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.13). The business had revenue of $23.32 million for the quarter, compared to analysts’ expectations of $21.48 million. MDxHealth had a negative return on equity of 987.86% and a negative net margin of 50.54%. As a group, equities analysts predict that MDxHealth SA will post -1.16 earnings per share for the current fiscal year.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.